Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zicronapine
- Development stage
- Phase 3
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zicronapine (Lu 31-130) is an atypical antipsychotic small molecule that was under development by Lundbeck for the treatment of schizophrenia. It is characterized by a unique pharmacological profile, acting as a potent antagonist at dopamine D1, D2, and serotonin 5-HT2A receptors. Unlike most atypical antipsychotics which prioritize D2 and 5-HT2A antagonism, zicronapine possesses high affinity for the D1 receptor, a feature intended to improve cognitive and negative symptoms of schizophrenia while minimizing extrapyramidal side effects. Despite reaching Phase III clinical trials, Lundbeck announced the discontinuation of zicronapine's development in 2012, citing that the clinical data did not support a competitive profile compared to existing therapies.
- Other names
- zicronapine
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on zicronapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zicronapine.